HK1248592A1 - 長效胰島素製劑 - Google Patents

長效胰島素製劑

Info

Publication number
HK1248592A1
HK1248592A1 HK18108478.4A HK18108478A HK1248592A1 HK 1248592 A1 HK1248592 A1 HK 1248592A1 HK 18108478 A HK18108478 A HK 18108478A HK 1248592 A1 HK1248592 A1 HK 1248592A1
Authority
HK
Hong Kong
Prior art keywords
long
insulin glargine
acting formulations
formulations
acting
Prior art date
Application number
HK18108478.4A
Other languages
English (en)
Inventor
萊茵哈德‧貝克
安克‧弗里克
彼得‧博德克
克里斯琴‧富爾斯特
沃納‧米勒
凱特林‧特奇
烏爾里克‧沃納
佩特拉‧露絲
伊莎貝爾‧舍特爾
Original Assignee
賽諾菲-安萬特
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44148980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1248592(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 賽諾菲-安萬特 filed Critical 賽諾菲-安萬特
Publication of HK1248592A1 publication Critical patent/HK1248592A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK18108478.4A 2010-05-19 2012-03-13 長效胰島素製劑 HK1248592A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10305532 2010-05-19
EP10305780 2010-07-13
EP11305140 2011-02-10

Publications (1)

Publication Number Publication Date
HK1248592A1 true HK1248592A1 (zh) 2018-10-19

Family

ID=44148980

Family Applications (5)

Application Number Title Priority Date Filing Date
HK18108478.4A HK1248592A1 (zh) 2010-05-19 2012-03-13 長效胰島素製劑
HK14111946A HK1198428A1 (zh) 2010-05-19 2012-03-13 長效胰島素製劑
HK15111312.1A HK1210435A1 (zh) 2010-05-19 2012-03-13 長效胰島素製劑
HK18108479.3A HK1248593A1 (zh) 2010-05-19 2012-03-13 長效胰島素製劑
HK15102982.9A HK1202428A1 (zh) 2010-05-19 2015-03-24 長效胰島素製劑

Family Applications After (4)

Application Number Title Priority Date Filing Date
HK14111946A HK1198428A1 (zh) 2010-05-19 2012-03-13 長效胰島素製劑
HK15111312.1A HK1210435A1 (zh) 2010-05-19 2012-03-13 長效胰島素製劑
HK18108479.3A HK1248593A1 (zh) 2010-05-19 2012-03-13 長效胰島素製劑
HK15102982.9A HK1202428A1 (zh) 2010-05-19 2015-03-24 長效胰島素製劑

Country Status (44)

Country Link
US (11) US20110301081A1 (zh)
EP (9) EP3824876B8 (zh)
JP (5) JP5269945B2 (zh)
KR (4) KR101989343B1 (zh)
CN (5) CN104622788A (zh)
AR (1) AR081200A1 (zh)
AU (1) AU2011202239C1 (zh)
BR (2) BR112012029131B1 (zh)
CA (1) CA2792669C (zh)
CL (1) CL2012003197A1 (zh)
CO (1) CO6640217A2 (zh)
CR (1) CR20120578A (zh)
CY (3) CY1115649T1 (zh)
DK (3) DK2387989T3 (zh)
DO (1) DOP2012000261A (zh)
EC (1) ECSP12012298A (zh)
ES (4) ES2509943T3 (zh)
FI (1) FI2571517T4 (zh)
GT (1) GT201200287A (zh)
HK (5) HK1248592A1 (zh)
HR (3) HRP20181028T4 (zh)
HU (2) HUE039355T2 (zh)
IL (2) IL221964A (zh)
JO (2) JO2944B1 (zh)
LT (2) LT2781212T (zh)
MA (1) MA34224B1 (zh)
MX (2) MX343489B (zh)
MY (1) MY156188A (zh)
NI (1) NI201200152A (zh)
NZ (1) NZ602541A (zh)
PE (2) PE20160781A1 (zh)
PH (2) PH12015501421B1 (zh)
PL (4) PL2781212T3 (zh)
PT (3) PT2387989E (zh)
RS (1) RS53559B1 (zh)
RU (3) RU2564104C2 (zh)
SG (2) SG185593A1 (zh)
SI (3) SI2387989T1 (zh)
TN (1) TN2012000478A1 (zh)
TR (2) TR201809475T4 (zh)
TW (4) TWI469787B (zh)
UY (1) UY33391A (zh)
WO (1) WO2011144673A2 (zh)
ZA (1) ZA201206998B (zh)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2371361T3 (es) 2005-12-28 2011-12-30 Novo Nordisk A/S Composiciones que comprenden una insulina acilada y zinc y método de producción de dichas composiciones.
EP2229407B1 (de) 2008-01-09 2016-11-16 Sanofi-Aventis Deutschland GmbH Neue insulinderivate mit extrem verzögertem zeit- / wirkungsprofil
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
MX2011004357A (es) 2008-10-30 2011-05-23 Novo Nordisk As Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyeccion menor que a diario.
JP5735960B2 (ja) * 2009-07-06 2015-06-17 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング メチオニンを含むインスリン製剤
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
WO2011058082A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
WO2012101251A1 (en) 2011-01-28 2012-08-02 Sanofi Human antibodies to pcsk9 for use in methods of treatment based on particular dosage regimens
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
DK2741765T3 (en) 2011-08-10 2016-06-13 Adocia Injectable solution of at least one type of basal insulin
FR2984749A1 (fr) * 2011-12-23 2013-06-28 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 en combinaison avec une hormone gastro-intestinale a visee therapeutique
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
FR2985428B1 (fr) * 2012-01-09 2016-05-27 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
BR112014016889A8 (pt) * 2012-01-09 2017-07-04 Adocia composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
FR2985429B1 (fr) * 2012-01-09 2016-07-29 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
DE112013002122T5 (de) 2012-04-18 2014-12-31 Waters Technologies Corporation Verfahren zur Quantifizierung von Polypeptiden mittels Massenspektrometrie
AR092862A1 (es) * 2012-07-25 2015-05-06 Hanmi Pharm Ind Co Ltd Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion
FR3001896B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le point isolectrique est compris entre 5,8 et 8,5 et un polymere anionique hydrophobise
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
FR3001895B1 (fr) 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
MX360420B (es) * 2012-12-19 2018-10-31 Wockhardt Ltd Una composicion acuosa estable que comprende insulina humana o un analogo o derivado de la misma.
CN104902920A (zh) 2012-12-21 2015-09-09 赛诺菲 作为glp1/gip双重激动剂或glp1/gip/胰高血糖素三重激动剂的毒蜥外泌肽-4衍生物
CN103893744B (zh) * 2012-12-24 2017-12-19 杭州九源基因工程有限公司 一种治疗糖尿病的药物制剂及其制备方法
WO2014102623A1 (en) * 2012-12-26 2014-07-03 Wockhardt Limited Pharmaceutical composition
TWI780236B (zh) 2013-02-04 2022-10-11 法商賽諾菲公司 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
US20160296602A1 (en) * 2013-03-20 2016-10-13 Novo Nordisk A/S Dosing Regimen
MY181626A (en) * 2013-04-03 2020-12-29 Sanofi Sa Treatment of diabetes mellitus by long-acting formulations of insulins
US20220202711A1 (en) * 2013-04-03 2022-06-30 Sanofi Treatment of Diabetes Mellitus by Long-Acting Formulations of Insulins
JP2016519127A (ja) 2013-04-30 2016-06-30 ノヴォ ノルディスク アー／エス 新規投与レジメン
US20140371141A1 (en) * 2013-06-17 2014-12-18 Sanofi-Aventis Deutschland Gmbh Insulin glargine/lixisenatide fixed ratio formulation
CN104587455A (zh) * 2013-10-31 2015-05-06 江苏万邦生化医药股份有限公司 一种胰岛素制剂
WO2015086729A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/gip receptor agonists
TW201609800A (zh) 2013-12-13 2016-03-16 賽諾菲公司 做為雙重ｇｌｐ－１／升糖素受體促效劑之艾塞那肽－４胜肽類似物
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
CN105899190B (zh) 2014-01-09 2022-06-14 赛诺菲 门冬胰岛素的稳定化药物制剂
AU2015205624A1 (en) 2014-01-09 2016-07-14 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
SG11201604708VA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
CN103830189A (zh) * 2014-03-04 2014-06-04 山东新时代药业有限公司 一种重组甘精胰岛素制剂及其制备方法
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
AR099936A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
WO2015150563A1 (en) 2014-04-04 2015-10-08 Sanofi Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
WO2016001862A1 (en) 2014-07-04 2016-01-07 Wockhardt Limited Extended release formulations of insulins
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
PL3229828T3 (pl) * 2014-12-12 2023-07-31 Sanofi-Aventis Deutschland Gmbh Formulacja o ustalonym stosunku insuliny glargine/liksysenatydu
CN104688678B (zh) * 2015-02-05 2017-11-17 通化东宝药业股份有限公司 一种甘精胰岛素注射液的制备方法及其制备的甘精胰岛素注射液
CN104688677B (zh) * 2015-02-05 2018-02-09 通化东宝药业股份有限公司 一种稳定的甘精胰岛素注射液及其制备方法
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
CN107922507B (zh) 2015-08-18 2022-04-05 瑞泽恩制药公司 抗pcsk9抑制性抗体用来治疗接受脂蛋白单采的高脂血症患者
PT3229828T (pt) * 2015-11-10 2023-06-29 Sanofi Aventis Deutschland Formulação de razão fixa de insulina glargina/lixisenatido
TW201731867A (zh) 2015-12-02 2017-09-16 賽諾菲公司 Ｆｇｆ２１變異體
CN105597087B (zh) * 2016-01-06 2019-04-26 山东新时代药业有限公司 一种甘精胰岛素注射液及其制备方法
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
WO2018055539A1 (en) 2016-09-22 2018-03-29 Wockhardt Limited Pharmaceutical composition containing buffered insulin glargine and glp-1 analogue
AR110301A1 (es) 2016-12-02 2019-03-13 Sanofi Sa Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
TW201833132A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物
CN110087671A (zh) 2016-12-22 2019-08-02 赛诺菲 具有优化的活性比率的fgf21化合物/glp-1r激动剂组合
US20190031774A1 (en) 2017-06-09 2019-01-31 Sanofi Biotechnology Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor
ES2969277T3 (es) * 2017-07-27 2024-05-17 Adocia Composiciones en forma de una solución acuosa inyectable que comprenden al menos insulina humana A21G y un supresor de glucagón con acción prandial
TW202015735A (zh) 2018-05-30 2020-05-01 法商賽諾菲公司 包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物
US20210275643A1 (en) 2018-06-21 2021-09-09 Sanofi Fgf21 compound / glp-1r agonist combinations with optimized activity ratio
WO2019243628A1 (fr) 2018-06-22 2019-12-26 Adocia Composition injectable a ph 7 comprenant un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes et au moins une insuline basale presentant au moins un effet prandial et un effet basal
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
WO2020239837A1 (en) 2019-05-29 2020-12-03 Sanofi Drug delivery device
KR20210144609A (ko) * 2020-05-22 2021-11-30 한미약품 주식회사 글루카곤, glp-1 및 gip 삼중 활성체의 지속형 결합체의 액상 제제
EP4175980A1 (en) 2020-07-02 2023-05-10 Sanofi Glp-1r agonistic peptides with reduced activity
EP4175660A1 (en) 2020-07-02 2023-05-10 Sanofi Glp-1r agonist / fgf21 fusion proteins
US20230302095A1 (en) * 2020-08-14 2023-09-28 Kyon Biotech Ag Increasing the efficacy of biological therapeutic molecules

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4960702A (en) 1985-09-06 1990-10-02 Codon Methods for recovery of tissue plasminogen activator
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
CH682806A5 (de) * 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
CH682805A5 (de) * 1992-02-24 1993-11-30 Medimpex Ets Anzeigeeinrichtung für ein Injektionsgerät.
DK0748213T3 (da) 1994-03-07 2004-08-02 Nektar Therapeutics Fremgangsmåder og sammensætninger til pulmonal indgivelse af insulin
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
CO4750643A1 (es) 1997-06-13 1999-03-31 Lilly Co Eli Formulacion estable de la insulina que contiene l-arginina y protamina
CA2306905A1 (en) 1997-10-24 1999-05-06 Eli Lilly And Company Fatty acid-acylated insulin analogs
US6978471B1 (en) 1999-05-25 2005-12-20 Thomson Licensing S.A. System for acquiring and processing broadcast programs and program guide data
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
DK1326630T3 (da) 2000-09-18 2008-09-15 Sanos Bioscience As Anvendelse af GLP-2-peptider
WO2002067969A2 (en) 2001-02-21 2002-09-06 Medtronic Minimed, Inc. Stabilized insulin formulations
US20030026872A1 (en) 2001-05-11 2003-02-06 The Procter & Gamble Co. Compositions having enhanced aqueous solubility and methods of their preparation
FR2827604B1 (fr) 2001-07-17 2003-09-19 Sanofi Synthelabo Nouveaux derives de 1-phenylsulfonyl-1,3-dihydro-2h-indol-2- one, un procede pour leur preparation et les compositions pharmaceutiques en contenant
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
US20100069293A1 (en) 2002-02-27 2010-03-18 Pharmain Corporation Polymeric carrier compositions for delivery of active agents, methods of making and using the same
US7115563B2 (en) 2002-05-29 2006-10-03 Insignion Holding Limited Composition and its therapeutic use
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
WO2004005342A1 (en) 2002-07-04 2004-01-15 Zealand Pharma A/S Glp-1 and methods for treating diabetes
DE10235168A1 (de) 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
GB0309154D0 (en) 2003-01-14 2003-05-28 Aventis Pharma Inc Use of insulin glargine to reduce or prevent cardiovascular events in patients being treated for dysglycemia
MXPA05003928A (es) 2003-01-21 2005-06-17 Ortho Tain Inc Un dispositivo dental y un sistema para reducir la cantidad de cooperacion del paciente para tratar una maloclusion utilizando el dispositivo dental.
GB0304822D0 (en) * 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
DE602004029630D1 (de) 2003-03-04 2010-12-02 Technology Dev Co Ltd Injizierbare Insulinzubereitung mit Langzeitwirkung und Verfahren zur dessen Herstellung und Verwendung
WO2005020927A2 (en) 2003-08-29 2005-03-10 Centocor, Inc. Method of promoting graft survival with anti-tissue factor antibodies
JP2007515235A (ja) * 2003-12-22 2007-06-14 ノボ・ノルデイスク・エー／エス 医薬液を保存するための、透明で、可撓性且つ不浸透性のプラスチック製容器
EP1701714A2 (en) 2004-01-07 2006-09-20 Nektar Therapeutics Improved sustained release compositions for pulmonary administration of insulin
US20080248999A1 (en) 2007-04-04 2008-10-09 Biodel Inc. Amylin formulations
WO2005097175A2 (en) 2004-03-31 2005-10-20 Centocor, Inc. Human glp-1 mimetibodies, compositions, methods and uses
BRPI0519241A2 (pt) 2004-12-22 2009-01-06 Centocor Inc agonistas, composiÇÕes, mÉtodos e usos de glp-1
US7879361B2 (en) 2005-01-04 2011-02-01 Gp Medical, Inc. Nanoparticles for drug delivery
WO2007038540A1 (en) 2005-09-26 2007-04-05 Medtronic, Inc. Prosthetic cardiac and venous valves
US8084420B2 (en) 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
DK1940243T3 (da) 2005-10-24 2011-11-14 Nestec Sa Kostfiberformulering og fremgangsmåde til indgivelse
AU2005338631B2 (en) 2005-11-30 2011-12-01 Generex Pharmaceuticals Inc. Orally absorbed pharmaceutical formulation and method of administration
US20100029558A1 (en) 2005-12-06 2010-02-04 Bristow Cynthia L Alpha1 proteinase inhibitor peptides methods and use
CN101454019A (zh) * 2006-04-12 2009-06-10 百达尔公司 速效和长效胰岛素联合制剂
JP2009539778A (ja) 2006-06-08 2009-11-19 ダイアベコア メディカル インコーポレイテッド インスリンオリゴマー誘導体
DE102006031962A1 (de) * 2006-07-11 2008-01-17 Sanofi-Aventis Deutschland Gmbh Amidiertes Insulin Glargin
JP2009544716A (ja) * 2006-07-27 2009-12-17 ノバルティス アクチエンゲゼルシャフト 肺送達のためのインスリン含有エアロゾル化可能製剤
EP2581441A1 (en) 2007-08-09 2013-04-17 Genzyme Corporation Method of treating autoimmune disease with mesenchymal stem cells
ES2558930T3 (es) 2007-08-13 2016-02-09 Novo Nordisk A/S Análogos de la insulina de acción rápida
PL2209800T3 (pl) 2007-11-16 2013-12-31 Novo Nordisk As Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
JP5352596B2 (ja) * 2008-01-04 2013-11-27 バイオデル， インコーポレイテッド 組織グルコースレベルの関数としてのインスリン放出のためのインスリン製剤
RU2495131C2 (ru) 2008-02-19 2013-10-10 Байокон Лимитид Способ получения рекомбинантного инсулина гларгина
WO2009143014A1 (en) 2008-05-23 2009-11-26 Amylin Pharmaceuticals, Inc. Glp-1 receptor agonist bioassays
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
WO2010028055A1 (en) 2008-09-02 2010-03-11 Biodel, Inc. Insulin with a basal release profile
HUE037449T2 (hu) 2008-10-17 2018-08-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
DE102008053048A1 (de) * 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
MX2011004357A (es) 2008-10-30 2011-05-23 Novo Nordisk As Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyeccion menor que a diario.
MX2011008416A (es) 2009-02-13 2011-09-08 Boehringer Ingelheim Int Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
US8709400B2 (en) 2009-07-27 2014-04-29 Washington University Inducement of organogenetic tolerance for pancreatic xenotransplant
RU2556340C2 (ru) 2009-07-31 2015-07-10 Санофи-Авентис Дойчланд Гмбх Композиция инсулина длительного действия
WO2011058082A1 (de) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Pharmazeutische zusammensetzung umfassend einen glp-1-agonisten und methionin
US20110118180A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
AR080669A1 (es) 2009-11-13 2012-05-02 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina
US20110118178A1 (en) 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin
RS52629B2 (sr) 2009-11-13 2019-11-29 Sanofi Aventis Deutschland Liksisenatid kao dodatna terapija insulin glarginu i metforminu za lečenje dijabetesa tipa 2
CN102933200B (zh) 2009-12-18 2015-11-25 莱迪杜德制药公司 包含磷脂的单相凝胶组合物
US20130085101A1 (en) 2010-02-22 2013-04-04 Case Western Reserve University Long-acting insulin analogue preparations in soluble and crystalline forms
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
UY33326A (es) 2010-04-14 2011-12-01 Sanofi Aventis Conjugados de insulina-sirna
US8637458B2 (en) 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
WO2011144674A2 (en) 2010-05-20 2011-11-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SBE4-ß-CYD
EP2389945A1 (en) 2010-05-28 2011-11-30 Sanofi-Aventis Deutschland GmbH Pharmaceutical composition comprising AVE0010 and insulin glargine
US9085757B2 (en) 2010-06-17 2015-07-21 Regents Of The University Of Minnesota Production of insulin producing cells
US8532933B2 (en) 2010-06-18 2013-09-10 Roche Diagnostics Operations, Inc. Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers
ES2606554T3 (es) 2010-08-30 2017-03-24 Sanofi-Aventis Deutschland Gmbh Uso de AVE0010 para la fabricación de un medicamento para el tratamiento de la diabetes mellitus de tipo 2
US20130261051A1 (en) 2010-10-27 2013-10-03 Thue Johansen Treating Diabetes Melitus Using Insulin Injections Administered With Varying Injection Intervals
WO2012065996A1 (en) 2010-11-15 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND MALTOSYL-ß-CYCLODEXTRIN
WO2012066086A1 (en) 2010-11-17 2012-05-24 Sanofi-Aventis Deutschland Gmbh PHARMACEUTICAL FORMULATION COMPRISING INSULIN GLARGINE AND SULFOBUTYL ETHER 7-ß-CYCLODEXTRIN
TW201236692A (en) 2011-02-02 2012-09-16 Sanofi Aventis Deutschland Prevention of hypoglycaemia in diabetes mellitus type 2 patients
CA2852056C (en) 2011-03-11 2021-08-10 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
EP2763691A1 (en) 2011-10-04 2014-08-13 Sanofi-Aventis Deutschland GmbH Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract

Also Published As

Publication number Publication date
RU2017146048A (ru) 2019-06-27
EP3424491A1 (en) 2019-01-09
JP2011241213A (ja) 2011-12-01
EP2781212B1 (en) 2018-04-04
RU2642662C2 (ru) 2018-01-25
UY33391A (es) 2011-10-31
US20200215163A1 (en) 2020-07-09
JP5269945B2 (ja) 2013-08-21
EP3400931A1 (en) 2018-11-14
CA2792669A1 (en) 2011-11-24
HRP20181026T1 (hr) 2018-08-24
HK1210435A1 (zh) 2016-04-22
HUE039355T2 (hu) 2018-12-28
US20190388511A1 (en) 2019-12-26
BR112012029131A2 (pt) 2016-09-13
KR20170072960A (ko) 2017-06-27
EP3824876A1 (en) 2021-05-26
ES2945208T3 (es) 2023-06-29
TW201607552A (zh) 2016-03-01
TWI469787B (zh) 2015-01-21
PE20160781A1 (es) 2016-08-26
EP4218723A3 (en) 2023-11-08
CN102319422A (zh) 2012-01-18
CY1120407T1 (el) 2019-07-10
RS53559B1 (en) 2015-02-27
US20160339084A1 (en) 2016-11-24
ECSP12012298A (es) 2012-12-28
JO2944B1 (en) 2016-03-15
HRP20181028T4 (hr) 2024-09-27
RU2564104C2 (ru) 2015-09-27
PT2571517T (pt) 2018-07-10
EP4218723A2 (en) 2023-08-02
CN107583037A (zh) 2018-01-16
CY1115649T1 (el) 2017-01-04
EP3824876B1 (en) 2023-02-22
CA2792669C (en) 2015-09-29
DK2387989T3 (da) 2014-10-20
NI201200152A (es) 2013-01-24
US20140206611A1 (en) 2014-07-24
JP2013147509A (ja) 2013-08-01
US20120122774A1 (en) 2012-05-17
CN103948913A (zh) 2014-07-30
EP2571517A2 (en) 2013-03-27
EP2571517B9 (en) 2024-10-16
PH12015501421A1 (en) 2015-09-07
FI2571517T4 (fi) 2024-09-20
JP2018044003A (ja) 2018-03-22
EP2387989A2 (en) 2011-11-23
SI2571517T1 (en) 2018-08-31
MX2019003693A (es) 2019-07-04
RU2011119988A (ru) 2012-11-27
CO6640217A2 (es) 2013-03-22
KR101913672B1 (ko) 2018-11-01
TW201427684A (zh) 2014-07-16
HK1202428A1 (zh) 2015-10-02
TWI496580B (zh) 2015-08-21
HK1248593A1 (zh) 2018-10-19
PH12019500517A1 (en) 2020-03-02
US20160228516A1 (en) 2016-08-11
CN107583038A (zh) 2018-01-16
JP6333775B2 (ja) 2018-05-30
HRP20181028T1 (hr) 2018-08-24
EP3636250A1 (en) 2020-04-15
DK2571517T3 (en) 2018-07-23
SI2781212T1 (en) 2018-08-31
EP2571517B2 (en) 2024-06-19
EP2571517B1 (en) 2018-04-04
DK2571517T4 (da) 2024-09-23
JOP20150245B1 (ar) 2021-08-17
US20110301081A1 (en) 2011-12-08
ES2676401T3 (es) 2018-07-19
PL2781212T3 (pl) 2018-08-31
US20200384087A1 (en) 2020-12-10
RU2015132860A (ru) 2017-02-09
DK2781212T3 (en) 2018-07-23
CN104622788A (zh) 2015-05-20
TR201809514T4 (tr) 2018-07-23
PE20130511A1 (es) 2013-05-02
AU2011202239C1 (en) 2017-03-16
GT201200287A (es) 2015-03-09
AU2011202239A1 (en) 2011-12-08
BR122019006884B1 (pt) 2022-08-23
NZ602541A (en) 2013-11-29
IL221964A (en) 2017-04-30
TR201809475T4 (tr) 2018-07-23
KR101486743B1 (ko) 2015-01-28
RU2017146048A3 (zh) 2021-07-01
JP2020040990A (ja) 2020-03-19
PH12015501421B1 (en) 2015-09-07
PT2781212T (pt) 2018-07-10
DOP2012000261A (es) 2013-01-31
SG10201510406YA (en) 2016-01-28
HUE039354T2 (hu) 2018-12-28
BR112012029131B1 (pt) 2020-03-10
IL251318A0 (en) 2017-05-29
CR20120578A (es) 2013-03-04
TWI605825B (zh) 2017-11-21
EP2387989A3 (en) 2012-04-18
EP2781212A1 (en) 2014-09-24
LT2571517T (lt) 2018-07-25
SI2387989T1 (sl) 2014-10-30
PL2571517T3 (pl) 2018-09-28
SG185593A1 (en) 2012-12-28
HK1198428A1 (zh) 2015-04-24
HRP20140860T1 (hr) 2014-10-24
PT2387989E (pt) 2014-09-15
US9345750B2 (en) 2016-05-24
LT2781212T (lt) 2018-07-25
MX343489B (es) 2016-11-08
KR20140109515A (ko) 2014-09-15
AU2011202239B2 (en) 2012-06-07
WO2011144673A2 (en) 2011-11-24
AR081200A1 (es) 2012-07-04
JP2015172068A (ja) 2015-10-01
PL2387989T3 (pl) 2014-12-31
TN2012000478A1 (en) 2014-04-01
ZA201206998B (en) 2013-05-29
EP3824876B8 (en) 2023-08-02
US20150164999A1 (en) 2015-06-18
ES2690302T3 (es) 2018-11-20
MA34224B1 (fr) 2013-05-02
EP3607935A1 (en) 2020-02-12
CL2012003197A1 (es) 2013-01-25
KR20180088752A (ko) 2018-08-06
EP2387989B1 (en) 2014-07-16
CY1121042T1 (el) 2019-12-11
TW201208695A (en) 2012-03-01
MX2012011278A (es) 2012-11-06
KR20130040824A (ko) 2013-04-24
WO2011144673A3 (en) 2012-05-03
IL251318B (en) 2018-12-31
TW201735941A (zh) 2017-10-16
US20210308225A1 (en) 2021-10-07
KR101989343B1 (ko) 2019-06-14
PL3824876T3 (pl) 2024-02-19
MY156188A (en) 2016-01-29
US20190046616A1 (en) 2019-02-14
ES2509943T3 (es) 2014-10-20

Similar Documents

Publication Publication Date Title
HK1248593A1 (zh) 長效胰島素製劑
PT2603232T (pt) Formulações estáveis de linaclotida
HK1256641A1 (zh) 長效的可注射的莫昔克丁配製劑
EP2576612A4 (en) INSULIN ANALOG
EP2699094A4 (en) TASTE-MASKED FORMULATIONS BY RALTEGRAVIR
SI2407155T1 (sl) Preparati na osnovi inekalcitola
EP2524698A4 (en) INSULIN PRODUCTION
TWM386637U (en) Improved structure of connector
PT3824876T (pt) Formulações de longa ação de insulinas
TWM401903U (en) Positioning structure of connector
TWM389178U (en) Improved structure of caster
TWM386662U (en) Improved structure of connector
TWM386655U (en) Improved structure of connector
TWM386647U (en) Improved structure of connector